The Emerging Role of Thiazolidinediones in the Treatment of Diabetes-Mellitus and Related Disorders

References

• Kahn R. Consensus development conference on insulin resistance. Diabetes Care 1998; 21: 310–314
   PubMed Web of Science ®Google Scholar
• Sohda T., Mizuno K., Momose Y., Ikeda H., Fujita T., Meguro K. Studies on antidiabetic agents. II. Novel thiazolidinedione derivatives as potent hypoglycemic and hpolipidemic agents. J. Med. Chem. 1992; 35: 2617–2626
   Google Scholar
• Horikoshi H., Yoshioka T. Troglitazone - a novel antidiabetic drug for treating insulin resistance. Drug Discovery Today 1998; 3: 79–88
   Web of Science ®Google Scholar
• Yoshioka T., Fujita T., Kanai T., Aizawa Y., Kurumada T., Hasegawa K., Horikoshi H. Studies on hindered phenols and analogous. 1. Hypolipidemic agents with ability to inhibit lipid peroxidation. J. Med. Chem. 1989; 32: 421–428
   Google Scholar
• Horikoshi H., Yoshioka T., Kawasaki T., Nakamura K-I., Matsunuma N., Yamaguchi K., Sasahara K. Troglitazone (CA-045) a new antidiabetic drug. Annu Rep. Sankyo. Res. Lab. 1994; 46: 1–57
   Google Scholar
• Bowen L., Stein P. P., Stevenson R., Shulman G. I. The effect of CP 68, 722, a thiazolidinedione derivative, on insulin sensitivity in lean and obese Zucker rats. Metabolism 1991; 40: 1025–1030
   PubMed Web of Science ®Google Scholar
• Oakes N. D., Kennedy C. J., Jenkins A. B., Laybulf D. R., Chisholm D. J., Kraegen E. W. A new anudiabetic agent, BRL-49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 1994; 43: 1203–1210
   PubMed Web of Science ®Google Scholar
• Berger J., Biswas C., Hayes N., Ventre J., Wu M., Doebber T. W. An anudiabetic thiazolidinedione potentiates insulin stimulation of glycogen synthase in rat adipose tissue. Endocrinology 1996; 137: 1984–1990
   PubMed Web of Science ®Google Scholar
• Fujiwara T., Wada M., Fukuda K., Fukami M., Yoshioka S., Yoshioka T., Horikoshi H. Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice. Metabolism. 1991; 40: 1213–1218
   Google Scholar
• Fujiwara T., Yoshioka S., Yoshioka T., Ushiyama I., Horikoshi H. Characterization of a new antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 1988; 37: 1849–1888
   Google Scholar
• Ikeda H., Taketomi S., Sugiyama Y., Shimura Y., Sohda T., Meguro K., Fujita T. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant rats. Drug Res. 1990; 40: 156–162
   PubMed Web of Science ®Google Scholar
• Stevenson R. W., McPherson R. K., Genereux P. E., Danbury B. H., Kreutter D. K. Antidiabetic agent englitazone enhances insulin action in nondiabetic rats without producing hypoglycemia. Metabolism 1991; 40: 1268–1274
   PubMed Web of Science ®Google Scholar
• Sohda T., Mizuno K., Momose Y., Ikeda H., Fujita T., Meguro K. Studies on antidiabetic agents II. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents. J. Med. Chem. 1992; 35: 2617–2626
   PubMed Web of Science ®Google Scholar
• Lefebvre A-M., Onsurbe J. P., Leitersdorf I., Briggs M. R., Paterniti J. R. Fruchart. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. Artertoscler Thromb Vasc Biol. 1997; 17: 1756–1764
   Google Scholar
• Kletzien R. F., Clarke S. D., Ulrich R. G. Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Molecular Pharmacology 1991; 41: 393–398
   Web of Science ®Google Scholar
• Lehmann J. M., Moore L. B., Smith-Oliver T. A., Wilkinson W. O., Wilson T. M., Kliewer S. A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activitated receptor (PPAR). J Biol. Chem. 1995; 270: 12953–12956
   PubMed Web of Science ®Google Scholar
• Wilson T. M., Cobb J. E., Cowan D. J., Wiethe R. W., Correa I. D., Prakash S. R., Beck K. D., Moore L. B., Kliewer S. A., Lehmann J. M. The structure-activity relationship between peroxisome proliferator-activated receptory agonism and the antihyperglycemic activity of thiazolidinediones. J. Med. Chem. 1996; 39: 665–668
   PubMed Web of Science ®Google Scholar
• Hotamisligil G. S., Shargill N. S., Spiegelman B. M. Adipose Expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 1993; 259: 87–91
   PubMed Web of Science ®Google Scholar
• Hotamisligil G. S., Arner P., Caro J. F., Atkinson R. L., Spiegelman B. M. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J. Clin. Invest. 1995; 95: 2409–2415
   PubMed Web of Science ®Google Scholar
• Hotamisligil G. S., Murray D. L., Choy L. N., Spiegelman B. M. Tumor necrosis factor α inhibits signaling from the insulin receptor. Proc. Natl. Acad. Sci. 1994; 91: 4854–4858
   PubMed Web of Science ®Google Scholar
• Miles P. D.G., Romeo O. M., Higo K., Cohen A., Rafaat K., Olefsky J. M. TNF-α-induced insulin resistance in vivo and its prevention by troglitazone. Diabetes 1997; 46: 1678–1683
   PubMed Web of Science ®Google Scholar
• Peraldi P., Xu M., Spiegelman B. M. Thiazolidinediones block tumor necrosis factor-α-induced inhibition of insulin signaling. J. Clin. Invest. 1997; 100: 1863–1869
   PubMed Web of Science ®Google Scholar
• Iwamoto Y., Kuzuya T., Matsuda A., Awata T., Kumakura S., Inooka G., Shiraishi I. Effect of new oral antidiabetic agent CS-045 on gluose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 1991; 14: 1083–1086
   PubMed Web of Science ®Google Scholar
• Suter S. L., Nolan J. J., Wallace P., Gumbiner B., Olefsky J. M. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992; 15: 193–203
   PubMed Web of Science ®Google Scholar
• Mimura K., Umeda F., Hiramatsu S., Taniguchi S., Ono Y., Nakashima N., Kobayashi K., Masakado M., Sako Y., Nawata H. Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type II diabetes. Diabetic Medicine 1994; 11: 685–691
   PubMed Web of Science ®Google Scholar
• Iwamoto Y., Kosaka K., Kuzuya T., Akanuma Y., Shigeta Y., Kaneko T. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 1996; 19: 151–156
   PubMed Web of Science ®Google Scholar
• Kumar S., Boulton A. J.M., Beck-Nielson H., Berthezene F., Muggeo M., Person B., Spinas G. A., Donoghue S., Lettis S., Stewart-Long P. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetdogia 1996; 39: 701–709
   PubMed Web of Science ®Google Scholar
• Ghazzi M. N., Perez J. E., Antonucci T. K., Driscoll J. H., Huang S. M., Faja B. W. The Troglitazone Study Group, and Whitcomb, R. Cardiac and glycerruc benefits of troglitazone treatment in NIDDM. Diabetes 1997; 46: 433–439
   Google Scholar
• Nolan J. J., Ludvik B., Beerdsen P., Joyce M., Olefsky J. M. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med. 1994; 331: 1188–1193
   PubMed Web of Science ®Google Scholar
• Depres J. P., Lamarche B., Mauriege P., Cantin B., Dagenais G. R., Moorjani S., Lupien P.-J. Hyperinsulinemia as an independent risk factor for ischemic heart disease. The New England Journal of Medicine 1996; 334: 952–957
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy I. M., Kotchen T. A. Epidemiologic, Physiologic, and clinical implications of hypertension and insulin resistance. Curr. Opin. Cardiol. 1993; 8: 757–764
   Web of Science ®Google Scholar
• Lind L., Berne C., Lithell H. Prevalence of insulin resistance in essential hypertension. J. Hypertens. 1995; 13: 1457–1462
   PubMed Web of Science ®Google Scholar
• Dubey R. K., Zhang H. Y., Reddy S. R., Boegehold M. A., Kotchen T. A. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am. J. Physiol. 1993; 265: R726–R732
   PubMed Web of Science ®Google Scholar
• Yoshioka S., Nishino H., Shiraki T., Ikeda K., Koike H., Okuna A., Wada M., Fujiwara T., Hosikoshi H. Anuhypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism 1993; 42: 75–80
   PubMed Web of Science ®Google Scholar
• Zhang H. Y., Reddy S. R., Kotchen T. A. Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity. Hypertension 1994; 24: 106–110
   PubMed Web of Science ®Google Scholar
• Valiquett T., Balagtas C., Whitcomb R. Troglitazone dose-response study in patients with NIDDM (abstract). Diabetes 1996; 44(suppl. 1)109
   Google Scholar
• Lohray B. B., Bhushan V., Bheema Rao P., Madhavan G. R., Murali N., Narasimha Roa K., Anantha Reddy K., Jajesh B. M., Ganapathi Reddy P., Chakraborti R., Vikramadithyan R. K., Rajagopalan R., Rao Mamidi N. V.s., Jajoo H. K., Subramaniam S. Novel thiazolidmedione-2–4-diones as potent euglycemic and hypolipidaemicagents. Journal of Medicinal Chemistry, in press
   Web of Science ®Google Scholar